A peptide-first approach to mutant p53: polymacrocyclic peptides engineered to keep small-molecule–like stability and cell permeability, while delivering biologic-grade binding to address TP53 hotspot mutations across solid tumors
Turning Mutations into Cancer Cures
Half of all cancers share one fatal flaw, a broken (mutated) p53.
Our mission is to restore p53. The most common genetic failure in cancer by using our polymacrocyclic peptides to reactivate hotspot TP53 mutations across solid tumors, unlocking one of oncology’s last untapped, truly tumor-agnostic therapeutic frontiers for millions of patients.
Our mission is to restore p53. The most common genetic failure in cancer by using our polymacrocyclic peptides to reactivate hotspot TP53 mutations across solid tumors, unlocking one of oncology’s last untapped, truly tumor-agnostic therapeutic frontiers for millions of patients.
Our New Therapeutic Paradigm
A completely novel therapeutic class that merges small-molecule-like stability and cell permeability with biologic-grade binding precision to repair the “undruggable” p53
High-Throughput Screening (HTS)
Activity-based high-throughput screening (HTS) of ultra-diverse peptide libraries to identify sequences that restore p53 DNA binding and transcriptional activity
Pioneering a New Class of Polymacrocyclic Peptides
GLP-1 drugs like Ozempic have ignited a peptide therapeutics boom, with the market projected to reach $260B by 2030. Peptides are the fastest-growing therapeutic class, yet limited access to architectural and functional diversity in discovery remains the critical bottleneck.
This creates a once-in-a-decade opportunity for new platforms to industrialize peptide discovery, scale innovation, and deliver repeatable high-value exits
This creates a once-in-a-decade opportunity for new platforms to industrialize peptide discovery, scale innovation, and deliver repeatable high-value exits
AI-driven complex, sophisticated, and unique peptide architectures
Our Technological Moat
An experiment-backed, target-linked industry largest data ocean (10^17) that compounds each design–test cycle: the engine for next-gen therapies.
Competitors manage only ~10^11
Competitors manage only ~10^11
Data nobody can access
Essentially unlimited customizability with non-standard building blocks. Ability to install complex functionalities and modular polymacrocyclic recombination
Redefining peptide design
Enzymatic macro/ poly-macrocyclization enabling any ring topology and non-canonical residues. An advantage nobody can close for years
Biology nobody can replicate
Contact us
You agree to our Terms and Conditions